Wednesday, July 8, 2026

Drug profile · INN

isoetharine hydrochloride

isoetharine hydrochloride (ISOETHARINE HYDROCHLORIDE) is a beta-2 adrenergic receptor agonist. Associated with Aldeyra Therapeutics. Route of administration: inhalation. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 0
News articles 0
Drug details — isoetharine hydrochloride
US status
approved
Class
Route
INHALATION
Patents
20
Programs
0
Data quality
0.89

Quick answer

isoetharine hydrochloride (ISOETHARINE HYDROCHLORIDE) is a beta-2 adrenergic receptor agonist. Associated with Aldeyra Therapeutics. Route of administration: inhalation. Current US regulatory status: approved.

Key facts

INN isoetharine hydrochloride
Brand ISOETHARINE HYDROCHLORIDE
Mechanism Beta-2 adrenergic receptor agonist
Target Beta-2 adrenergic receptor
Route INHALATION
Formulation SOLUTION

Mechanism of action

Beta-2 adrenergic receptor agonist

Primary target: Beta-2 adrenergic receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. albuterol Beta-2 adrenergic receptor agonist
  2. albuterol sulfate Beta-2 adrenergic receptor agonist
  3. arformoterol tartrate Beta-2 adrenergic receptor agonist
  4. formoterol fumarate Beta-2 adrenergic receptor agonist
  5. levalbuterol hydrochloride Beta-2 adrenergic receptor agonist
  6. metaproterenol sulfate Beta-2 adrenergic receptor agonist
  1. US 12240816

    Deuterated compounds and uses thereof

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12029735

    Polymorphic compounds and uses thereof

    Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12006298

    Polymorphic compounds and uses thereof

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11845722

    Deuterated compounds and uses thereof

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11724987

    Compositions and methods of treating retinal disease

    Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11590089

    Beta-2 selective adrenergic receptor agonists

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11459300

    Deuterated compounds and uses thereof

    Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11312692

    Polymorphic compounds and uses thereof

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 11046650

    Deuterated compounds and uses thereof

    Expires Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 10913722

    Compositions and methods of treating retinal disease

    Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 10550085

    Deuterated compounds and uses thereof

    Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 10414732

    Polymorphic compounds and uses thereof

    Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 10202348

    Compositions and methods of treating retinal disease

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 9896419

    Compositions and methods of treating retinal disease

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 9650342

    Compositions and methods of treating retinal disease

    Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 9604997

    Peri-carbinols

    Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 9364471

    Compositions and methods of treating retinal disease

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 9265759

    Compositions and methods of treating retinal disease

    Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 9266928

    Deletion of the beta 20-21 loop in HIV GP120 exposes the CD4 binding site for improved antibody binding and antibody induction

    Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 8628782

    Deletion of the beta 20-21 loop in HIV gp120 exposes the CD4 binding site for improved antibody binding and antibody induction

    Expires Mon Jan 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is isoetharine hydrochloride?

isoetharine hydrochloride (ISOETHARINE HYDROCHLORIDE) is a beta-2 adrenergic receptor agonist. Associated with Aldeyra Therapeutics. Route of administration: inhalation. Current US regulatory status: approved.

What is the brand name for isoetharine hydrochloride?

ISOETHARINE HYDROCHLORIDE is a marketed brand name for isoetharine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of isoetharine hydrochloride?

isoetharine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.